Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NexMed, a specialty CRO with a pipeline of products based on the NexACT technology, has released results from a pre-clinical study showing that calcipotriene 0.005% and betamethasone dipropionate 0.064%, when formulated with NexACT, results in a topical treatment which shows bioequivalency in efficacy to Talconex, one of the topical treatments marketed for patients with mild to moderate psoriasis.
Subscribe to our email newsletter
NexMed has conducted two pre-clinical studies on its NexACT-based topical psoriasis treatment. The first efficacy study using a cadaver skin model showed that the NexACT-based formulation of the two active drugs delivered the same level of drugs (measured in ug/cm2/hour) as compared to the commercial Talconex product.
Additionally, in a second efficacy study, using the DNFB induced allergic contact dermatitis (ACD) pig model, results showed that the NexACT-based formulation lowered the clinical inflammation and erythema score in sick animals.
Bassam Damaj, president and CEO of NexMed, said: “We have a competitive psoriasis treatment under development. Our NexACT-based formulation is novel and does not infringe on the marketed topical treatments.
“Our data, though early stage, shows bioequivalency to Talconex, and further supports the versatility of the NexACT technology and its applicability to a broad range of disease states. We look forward to commencing partnering discussions for continued development of this product candidate.”